COVID-19 cases are on the rise in Chicago, and getting an updated vaccine engineered to target new variants is important, health officials warn, but availability and insurance hiccups have left some Chicagoans scrambling.
New vaccines developed by Pfizer-BioNTech and Moderna meant to target recent subvariants, including XBB.1.5 and EG.5, were approved last month, but the rollout is working a bit differently than the first round of COVID-19 vaccines, causing bumps in the road.
